Wire · opportunities
Are Concerns Over Avacopan Efficacy Overblown?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
A real-world multicenter Italian study of 46 patients treated with avacopan for ANCA-associated vasculitis found high clinical remission rates, improved renal function, and significant corticosteroid dose reduction despite previous concerns about the drug's trial data integrity and regulatory status in the US and Europe.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face renewed market opportunity as real-world data supports avacopan's efficacy despite trial doubts. This opens a door to advocate for patient access and tailor safety monitoring protocols locally.
◆ Coverage
1 source · 12 Oct 2026
◆ Related on Wire
◆ Topics